The effect of eplerenone on ischemia reperfusion injury in human myocardium

The effect of eplerenone on ischemia reperfusion injury in human myocardium - Eplerenone and ischemia-reperfusion injury

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON40313

Enrollment

Registered

2014-01-23

Start date

2014-03-11

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemia reperfusion injury myocardial infarction

Interventions

The intervention occurs ex vivo in the organ bath: adminstration of eplerenone with or without the adenosine receptor antagonist caffeine.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age >18 years - cardiac surgery with extracorporeal circulation

Exclusion criteria

Exclusion criteria: * Use of theophylline * Use of sulfonylureas * Use of oral antiarrhythmics ( not betablockers) * Atrial arrhythmias * Right ventricular failure * Known atrial enlargement

Design outcomes

Primary

Measure	Time frame
The effect of eplerenone of the recovery of contractile function after simulated ischemia and reperfusion	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)